Agenebio
UEI: YZWJGZMT3MN5
• CAGE: 62ZH3
Overview
Awardee Type
Parent
Company Description
AgeneBio's mission is to discover and develop innovative therapeutics for patients at risk for neurological and psychiatric conditions. Our lead late-stage clinical program is focused on prevention of Alzheimer’s dementia.
Name
Agenebio
Website
Headquarters
Baltimore, MD
United States
United States
Most Recent Award
Sept. 1, 2022
Calculating
Federal grant recipient
AGENEBIO, INC.
dba AGENEBIO INC
(UEI YZWJGZMT3MN5, CAGE 62ZH3)
is headquartered in Baltimore MD.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in June 2008 and
federally registered in
July 2010.
Federal Award Analysis
Agenebio federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
AGENEBIO, INC.
DBA
AGENEBIO INC
UEI
YZWJGZMT3MN5
CAGE Code
62ZH3
SBA Certifications
None
Self Certifications
Woman Owned Business
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
June 4, 2008
Initial Registration
July 21, 2010
Last Registration
Dec. 9, 2024
Registration Activation
Dec. 9, 2024
Registration Expiration
Dec. 5, 2025
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Accepts Credit Cards
No
People
Vendor contacts at Agenebio
Grant Awards
Agenebio direct grants
Teaming Partners
Disclosed awardee sub and prime contract and grant relationships
Agenebio